The Department of General and Visceral Surgery at University Medical Center Freiburg offers
1 Postdoc Position
The appointment can start any time after February 1st in 2020.
Applications are invited for a Postdoc position to work with Dr. Dietrich A. Ruess (Department of General and Visceral Surgery, University Medical Center Freiburg) in a newly established Max-Eder Junior Research Group, funded by the German Cancer Aid (Stiftung Deutsche Krebshilfe), aiming at deciphering cellular signaling mechanisms and their interaction with the tumor microenvironment and immune response in Pancreatic Ductal Adenocarcinoma. Novel therapeutic approaches are being explored.
Successful applicants will combine cell/molecular biology methods in human and murine samples with analysis of complex genetic mouse tumor models of pancreatic cancer, including preclinical translation in therapy trials. The Junior Group is based in the Zentrum für Translationale Zellforschung (ZTZ), a newly built research facility equipped with state-of-the-art instrumentation and home to a large number of excellent research groups focusing on oncology and immunology.
- the unique opportunity for engaging in the shaping-process of a nascent and ambitious Junior Research Group
- candidates should have a background in molecular biology, oncology, immunology or closely related field
- experience in cell/molecular biology analyses (PCR, WB, IHC/IHF, Flow cytometry) and with (genetically engineered) rodent animal models is highly desirable
The position is fixed-term for 30 months (third-party-funded) in fulltime, E13 100 % (PostDoc), starting 01.02.2020 with option for extension.
Feel free to reach out for additional information. Please submit your application including CV, list of publications, statement of research interests and names and email addresses of at least two references.
Klinik für Allgemein- und Viszeralchirurgie
Dr. Dietrich Ruess
Hugstetter Str. 55, 79106 Freiburg
For further information please contact us:
The project is related to the following publication:
Ruess DA, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nature Medicine. 2018. 24(7):954-960